TELA Bio Inc (TELA) — Titan Protect Analysis

TELA

TELA Bio Inc

Healthcare · ·

$0.88

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$42M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.69

Based on estimated future earnings — lower means cheaper

Rev Growth

+2.9%

Year-over-year revenue change

Profit Margin

-49.3%

How much profit the company keeps from each dollar of revenue

ROE

-616.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.00

+127% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About TELA Bio Inc

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex

https://www.telabio.com

Country: United States Employees: 218 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.733

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0986

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.676

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-61.0%

Historical annualised return based on price data

Max Drawdown

-90.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$2.20

60% below the year high

52W Low

$0.50

76% above the year low

Avg Volume

185,242

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.79

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

67.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-55.2%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$81M

Total revenue over the last 12 months

Net Income

$-39,840,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.25

Target Median

$2.00

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go